Ernest Dorflinger

2.2k total citations · 1 hit paper
18 papers, 1.7k citations indexed

About

Ernest Dorflinger is a scholar working on Neurology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Ernest Dorflinger has authored 18 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 7 papers in Psychiatry and Mental health and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Ernest Dorflinger's work include Parkinson's Disease Mechanisms and Treatments (10 papers), Neurological disorders and treatments (6 papers) and Epilepsy research and treatment (3 papers). Ernest Dorflinger is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (10 papers), Neurological disorders and treatments (6 papers) and Epilepsy research and treatment (3 papers). Ernest Dorflinger collaborates with scholars based in United States, Switzerland and United Kingdom. Ernest Dorflinger's co-authors include Simon C.J. Pedder, DORIS A. CHERNIK, W. R. Wayne Martin, Marie Saint‐Hilaire, A. H. Rajput, Heidi Shale, Cheryl Waters, Glenn T. Stebbins, Matthias Kurth and J. Eric Ahlskog and has published in prestigious journals such as Neurology, Neurobiology of Aging and Movement Disorders.

In The Last Decade

Ernest Dorflinger

17 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

2017 411 citations Susanne Ostrowitzki, Robert Lasser et al. Alzheimer s Research & Therapy profile →

Peers

Ernest Dorflinger

NEURO

CMN

PHYSI

PMH

Ana M. Catafau Spain

Zsolt Cselényi Sweden

Akihiko Koyama United States

N. P. L. G. Verhoeff Netherlands

Laëtitia Lemoine Sweden

Marta Marquié Spain

Heather McCann Australia

Akira Ueki Japan

Meixiang Yu United States

Judes Poirier Canada

Ana M. Catafau Spain

Ernest Dorflinger

411 ×0.5

NEURO

430 ×1.1

CMN

456 ×1.2

PHYSI

640 ×1.7

PMH

219 ×1.0

Citations per year, relative to Ernest Dorflinger Ernest Dorflinger (= 1×) peers Ana M. Catafau

Countries citing papers authored by Ernest Dorflinger

Since Specialization

Citations

This map shows the geographic impact of Ernest Dorflinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernest Dorflinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernest Dorflinger more than expected).

Fields of papers citing papers by Ernest Dorflinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernest Dorflinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernest Dorflinger. The network helps show where Ernest Dorflinger may publish in the future.

Co-authorship network of co-authors of Ernest Dorflinger

This figure shows the co-authorship network connecting the top 25 collaborators of Ernest Dorflinger. A scholar is included among the top collaborators of Ernest Dorflinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernest Dorflinger. Ernest Dorflinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Ostrowitzki, Susanne, Robert Lasser, Ernest Dorflinger, et al.. (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer s Research & Therapy. 9(1). 95–95. 411 indexed citations breakdown →

Nikolcheva, Tania, Robert Lasser, Susanne Ostrowitzki, et al.. (2016). CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD. Neurobiology of Aging. 39. S28–S29. 3 indexed citations

Scheltens, Philip, Tania Nikolcheva, Robert Lasser, et al.. (2015). DT‐01‐02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. Alzheimer s & Dementia. 11(7S_Part_7). 7 indexed citations

Lasser, Robert, Susanne Ostrowitzki, Philip Scheltens, et al.. (2015). DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial. Alzheimer s & Dementia. 11(7S_Part_7). 14 indexed citations

Umbricht, Daniel, Daniela Alberati, Meret Martin‐Facklam, et al.. (2014). Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia. JAMA Psychiatry. 71(6). 637–637. 186 indexed citations

Umbricht, Daniel, et al.. (2011). P.3.e.009 Glycine reuptake inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. European Neuropsychopharmacology. 21. S517–S518. 2 indexed citations

Acuña, Gonzalo, Dorothee Foernzler, Diane U. Leong, et al.. (2002). Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. The Pharmacogenomics Journal. 2(5). 327–334. 57 indexed citations

Welsh, Mickie, Ernest Dorflinger, DORIS A. CHERNIK, & Cheryl Waters. (2000). Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone. Movement Disorders. 15(3). 497–502. 19 indexed citations

Hauser, Robert A., Eric Molho, Heidi Shale, Simon C.J. Pedder, & Ernest Dorflinger. (1998). A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Movement Disorders. 13(4). 643–647. 37 indexed citations

10.

Rajput, A. H., W. R. Wayne Martin, Marie Saint‐Hilaire, Ernest Dorflinger, & Simon C.J. Pedder. (1998). Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon. Neurology. 50(5_suppl_5). S54–9. 106 indexed citations

11.

Kurth, Matthias, Charles H. Adler, Melissa St Hilaire, et al.. (1997). Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations. Neurology. 48(1). 81–87. 151 indexed citations

12.

Dupont, E., et al.. (1997). Tolcapone added to levodopa in stable parkinsonian patients: A double‐blind placebo‐controlled study. Movement Disorders. 12(6). 928–934. 45 indexed citations

13.

Rajput, A. H., W. R. Wayne Martin, Marie Saint‐Hilaire, Ernest Dorflinger, & Simon C.J. Pedder. (1997). Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology. 49(4). 1066–1071. 126 indexed citations

14.

Waters, Cheryl, Matthias Kurth, Lisa M. Shulman, et al.. (1997). Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology. 49(3). 665–671. 114 indexed citations

15.

Goetz, Christopher G., Glenn T. Stebbins, Heidi Shale, et al.. (1994). Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessment. Movement Disorders. 9(4). 390–394. 228 indexed citations

16.

Fowler, Joanna S., Nora D. Volkow, Jean Logan, et al.. (1994). Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal. Synapse. 18(2). 86–93. 121 indexed citations

17.

Fowler, Joanna S., Nora D. Volkow, Jean Logan, et al.. (1993). Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease. Neurology. 43(10). 1984–1984. 67 indexed citations

18.

Armstrong, William H., Ernest Dorflinger, Owen T. Anderson, & Bennett R. Willeford. (1981). A physical chemistry experiment in Mossbauer spectroscopy. Journal of Chemical Education. 58(6). 515–515.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact